VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.
- Mechanism
- Curator reviewed
VT-111 operates through a novel mechanism of action by promoting an anti-inflammatory response that reduces monocyte/macrophage infiltration into damaged vasculature via the mammalian urokinase type plasminogin activator receptor (uPAR). Monocyte/macrophages are key cellular players in the inflammation process and are considered to have an important role in atherosclerosis, restenosis and vasculopathy. Studies indicate that VT-111 achieves this anti-inflammatory result through the inhibition of the human serine proteases that regulate inflammatory influx of monocyte/macrophages into damaged tissues.
- Primary indication
- Investigated for use/treatment in cardiovascular disorders, coronary artery disease, and inflammatory disorders (unspecified).Curator reviewed
- Also known as
- Serine proteinase-1 · Serp-1
- Code names
- VT-111
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with VT-111, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account